Atlas market file · Etf · United States
Direxion Daily S&P Biotech Bull 3X ETFLABU
- Last close
- 277.23
- Change
- +5.69%
- 96-bar range
- 133.96 – 333.00
- As of
- 7 Aug 2026
Direxion Daily S&P Biotech Bull 3X ETF is an exchange-traded fund listed as LABU on AMEX. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
LABU
Etf · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+94.71% over the window).
Source rail: Yahoo Finance chart API (LABU). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for LABU. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
LABU public profile
Exchange-traded fund. Direxion Daily S&P Biotech Bull 3X ETF is connected to current market context, cited company sources and its retained research file.
Direxion Daily S&P Biotech Bull 3X ETF trades as LABU on AMEX. Direxion Daily S&P Biotech Bull 3X ETF (LABU) has a latest verified close of 277.23, up 5.69%, dated 7 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. LABU stays in the main symbols index until Atlas has enough listing or name evidence for a narrower browse group.
What changed for Direxion Daily S&P Biotech Bull 3X ETF today
LABU, the Direxion Daily S&P Biotech Bull 3X ETF, is a concentrated ETF designed to provide triple the daily performance of the S&P Biotechnology Select Industry Index. This means that if the index goes up by 1%, LABU aims to go up by 3%, and vice versa. The fund achieves this through the use of derivatives, such as swaps and futures, which amplify the underlying index's returns.
The top holdings of LABU include major biotech companies like Amgen, Biogen, and Regeneron, which together make up a significant portion of the fund's portfolio. This concentration in a few large-cap biotech stocks means that LABU's performance is heavily influenced by the fortunes of these companies. The fund's high expense ratio of 0.95% is also worth noting, as it can eat into returns over time.
LABU is marketed as a way to gain exposure to the biotech sector with the potential for outsized gains, but it comes with significant risks. The fund's concentrated nature makes it highly volatile and suitable only for short-term traders. Over longer periods, the compounding effects of daily rebalancing can lead to significant deviations from the underlying index's performance.
On Nasdaq, LABU has seen recent market activity with a notable spike in trading volume, reflecting increased investor interest in the biotech sector. However, potential the source directs readers to be aware of the fund's high risk profile and the impact of fees on long-term returns. The fund's performance is closely tied to the underlying index, and any significant movements in the biotech sector can have a magnified effect on LABU.
While LABU offers the potential for amplified gains, it also comes with the risk of amplified losses. The source directs readers to carefully consider their risk tolerance and investment horizon before diving in. The fund's performance is highly dependent on the daily movements of the underlying index, and its suitability for long-term investing is questionable.
Sources & evidence · 3 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
LABU technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on LABU
FreedomCore Atlas can expand this public profile into source-led research files with holdings and concentration, index methodology, exposure and overlap, fees and tracking difference, and liquidity context. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep LABU research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
LABU FAQ
What is Direxion Daily S&P Biotech Bull 3X ETF (LABU)?Direxion Daily S&P Biotech Bull 3X ETF (LABU) has a latest verified close of 277.23, up 5.69%, dated 7 Aug 2026. Use this page to check the price chart, company...
Direxion Daily S&P Biotech Bull 3X ETF (LABU) has a latest verified close of 277.23, up 5.69%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for LABU?Direxion Daily S&P Biotech Bull 3X ETF (LABU) has a latest verified close of 277.23, up 5.69%, dated 7 Aug 2026. It brings the latest available chart, company context,...
Direxion Daily S&P Biotech Bull 3X ETF (LABU) has a latest verified close of 277.23, up 5.69%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. LABU stays in the main symbols index until Atlas has enough listing or name evidence for a narrower browse group.
How often is the LABU page updated?The LABU public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The LABU public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for LABU?The LABU file starts with Nasdaq Trader and TradingView AMEX:LABU. The page separates verified market context from company evidence and shows open evidence gaps instead...
The LABU file starts with Nasdaq Trader and TradingView AMEX:LABU. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on LABU?Yes. The workstation can open LABU, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open LABU, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this LABU page investment advice?No. The LABU page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The LABU page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →